TPTX Insider Trading Activity and SEC Form 4 Filings
TPTX insider trading summary
No open-market insider purchases or sales of Turning Point Therapeutics, Inc. (TPTX) have been reported on SEC Form 4 in the past 12 months.
Latest TPTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 27, 2022 | Paolo Tombesi | EVP & Chief Financial Officer | Sell | $89K (1,183 @ $74.94) |
| Feb 9, 2022 | Andrew John Partridge | EVP & Chief Commercial Officer | Sell | $8K (221 @ $36.30) |
| Feb 9, 2022 | Siegfried Reich | EVP & Chief Scientific Officer | Sell | $14K (397 @ $36.30) |
| Feb 9, 2022 | Athena Countouriotis | President & CEO | Sell | $108K (2,971 @ $36.30) |
| Feb 9, 2022 | Annette North | EVP & General Counsel | Sell | $24K (669 @ $36.30) |
| Feb 9, 2022 | Mohammad Hirmand | EVP & Chief Medical Officer | Sell | $24K (669 @ $36.30) |
| Aug 30, 2021 | Annette North | EVP, General Counsel & Secty. | Sell | $800K (10,000 @ $80.00) |
| Jul 14, 2021 | Andrew John Partridge | EVP & Chief Commercial Officer | Sell | $140K (1,869 @ $74.90) |
| Jun 21, 2021 | Mark J Alles | Director | Buy | $163K (2,000 @ $81.34) |
| Jun 15, 2021 | Annette North | EVP, General Counsel & Secty. | Sell | $516K (6,634 @ $77.82) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.